Published in J Immigr Minor Health on December 04, 2008
Review of prostate cancer research in Nigeria. Infect Agent Cancer (2011) 0.87
Addressing cancer control needs of African-born immigrants in the US: a systematic literature review. Prev Med (2014) 0.83
The role of knowledge, language, and insurance in endorsement of cancer screening in women of African origin. Prev Med Rep (2015) 0.77
Development and assessment of an evidence-based prostate cancer intervention programme for black men: the W.O.R.D. on prostate cancer video. Ecancermedicalscience (2014) 0.75
Epidemiology of prostate and kidney cancer in the Aboriginal population of Canada: A systematic review. Can Urol Assoc J (2017) 0.75
Determinants of Prostate Cancer Screening Intentions of Young Black Men Aged 18 to 40 Years. J Racial Ethn Health Disparities (2016) 0.75
Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet (2007) 14.37
Demonstrating stratification in a European American population. Nat Genet (2005) 9.49
The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer. Nat Genet (2009) 6.99
Transferability of tag SNPs in genetic association studies in multiple populations. Nat Genet (2006) 4.78
8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A (2010) 3.37
A common 8q24 variant in prostate and breast cancer from a large nested case-control study. Cancer Res (2007) 3.08
Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol (2005) 2.82
Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell (2013) 2.56
Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Res (2009) 2.54
Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol (2012) 2.44
Replication of prostate cancer risk loci in a Japanese case-control association study. J Natl Cancer Inst (2009) 2.39
Evidence-based clinical practice guidelines for integrative oncology: complementary therapies and botanicals. J Soc Integr Oncol (2009) 2.35
Surgical management of melanoma-in-situ using a staged marginal and central excision technique. Ann Surg Oncol (2008) 2.11
PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells. Int Immunol (2009) 2.10
Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst (2007) 2.03
Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol (2003) 1.83
Admixture mapping of 15,280 African Americans identifies obesity susceptibility loci on chromosomes 5 and X. PLoS Genet (2009) 1.81
Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev (2005) 1.81
Genetic variation in the HSD17B1 gene and risk of prostate cancer. PLoS Genet (2005) 1.67
Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations. J Natl Cancer Inst (2013) 1.63
Thermal dose is related to duration of local control in canine sarcomas treated with thermoradiotherapy. Clin Cancer Res (2005) 1.63
Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth. Proc Natl Acad Sci U S A (2011) 1.59
Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clin Cancer Res (2010) 1.54
Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys (2003) 1.42
Common genetic variation in IGF1 and prostate cancer risk in the Multiethnic Cohort. J Natl Cancer Inst (2006) 1.41
Analysis of the 10q11 cancer risk locus implicates MSMB and NCOA4 in human prostate tumorigenesis. PLoS Genet (2010) 1.40
mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol (2011) 1.40
Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors. Clin Cancer Res (2006) 1.37
Fatty acid synthase polymorphisms, tumor expression, body mass index, prostate cancer risk, and survival. J Clin Oncol (2010) 1.37
Genetic and functional analyses implicate the NUDT11, HNF1B, and SLC22A3 genes in prostate cancer pathogenesis. Proc Natl Acad Sci U S A (2012) 1.34
Common genetic variation in the sex steroid hormone-binding globulin (SHBG) gene and circulating shbg levels among postmenopausal women: the Multiethnic Cohort. J Clin Endocrinol Metab (2005) 1.32
Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation. Cancer Res (2005) 1.29
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res (2009) 1.27
Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res (2004) 1.24
Comprehensive association testing of common genetic variation in DNA repair pathway genes in relationship with breast cancer risk in multiple populations. Hum Mol Genet (2007) 1.24
Radiotherapy influences local control in patients with desmoplastic melanoma. Cancer (2013) 1.23
An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.22
Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev (2010) 1.21
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results. J Clin Oncol (2006) 1.21
Integrative Oncology Practice Guidelines. J Soc Integr Oncol (2007) 1.21
Common genetic variation in IGF1, IGFBP-1, and IGFBP-3 in relation to mammographic density: a cross-sectional study. Breast Cancer Res (2007) 1.20
A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians. Hum Mol Genet (2010) 1.18
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) (2011) 1.17
Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. Cancer Res (2006) 1.16
Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer (2010) 1.14
Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev (2006) 1.14
Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res (2010) 1.10
Genetic and functional analysis of CHEK2 (CHK2) variants in multiethnic cohorts. Int J Cancer (2007) 1.09
Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn Reson Med (2006) 1.08
Genetic determinants of circulating insulin-like growth factor (IGF)-I, IGF binding protein (BP)-1, and IGFBP-3 levels in a multiethnic population. J Clin Endocrinol Metab (2007) 1.07
Chromosome 8q24-Associated Cancers and MYC. Genes Cancer (2010) 1.07
Snx3 regulates recycling of the transferrin receptor and iron assimilation. Cell Metab (2013) 1.06
Extracellular pH and P-31 magnetic resonance spectroscopic variables are related to outcome in canine soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res (2006) 1.05
Prostate cancer health and cultural beliefs of black men: The Florida Prostate Cancer Disparity Project. Infect Agent Cancer (2011) 1.05
A large study of androgen receptor germline variants and their relation to sex hormone levels and prostate cancer risk. Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. J Clin Endocrinol Metab (2010) 1.04
Biomarkers on melanoma patient T cells associated with ipilimumab treatment. J Transl Med (2012) 1.04
Allelic selection of amplicons in glioblastoma revealed by combining somatic and germline analysis. PLoS Genet (2010) 1.02
Complementary therapies and integrative oncology in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest (2007) 1.01
A prospective phase II single-institution trial of sunitinib for recurrent malignant glioma. J Neurooncol (2012) 1.00
Dynamic contrast-enhanced magnetic resonance imaging as a predictor of clinical outcome in canine spontaneous soft tissue sarcomas treated with thermoradiotherapy. Clin Cancer Res (2009) 0.98
Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev (2006) 0.97
Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother (2010) 0.97
DCE-MRI parameters have potential to predict response of locally advanced breast cancer patients to neoadjuvant chemotherapy and hyperthermia: a pilot study. Int J Hyperthermia (2009) 0.96
Common genetic variation at PTEN and risk of sporadic breast and prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 0.96
Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? Ann Surg Oncol (2013) 0.96
Cancer cachexia: traditional therapies and novel molecular mechanism-based approaches to treatment. Curr Treat Options Oncol (2010) 0.96
A systematic approach to understand the functional consequences of non-protein coding risk regions. Cell Cycle (2010) 0.96
Candidate tumor suppressor gene SLC5A8 is frequently down-regulated by promoter hypermethylation in prostate tumor. Cancer Detect Prev (2007) 0.95
Calling amplified haplotypes in next generation tumor sequence data. Genome Res (2011) 0.95
Effect of longitudinal oxygen gradients on effectiveness of manipulation of tumor oxygenation. Cancer Res (2003) 0.94
Quantitative real-time RT-PCR monitoring of BCR-ABL in chronic myelogenous leukemia shows lack of agreement in blood and bone marrow samples. Int J Oncol (2006) 0.93
African-Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk factors. Infect Agent Cancer (2007) 0.92
Power to detect selective allelic amplification in genome-wide scans of tumor data. Bioinformatics (2009) 0.91
A clinical model of dermal wound angiogenesis. Wound Repair Regen (2003) 0.88
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin Cancer Res (2003) 0.88
Deconvoluting complex tissues for expression quantitative trait locus-based analyses. Philos Trans R Soc Lond B Biol Sci (2013) 0.87
Relation between pO2, 31P magnetic resonance spectroscopy parameters and treatment outcome in patients with high-grade soft tissue sarcomas treated with thermoradiotherapy. Int J Radiat Oncol Biol Phys (2005) 0.87
Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. Neurotoxicology (2005) 0.87
Macrocytic anemia and mitochondriopathy resulting from a defect in sideroflexin 4. Am J Hum Genet (2013) 0.86
The genetics of cancer risk. Cancer J (2011) 0.85
Circulating colony stimulating factor-1 and breast cancer risk. Cancer Res (2008) 0.85
Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm. Ann Surg Oncol (2012) 0.85
Inherited variants in the chemokine CCL2 gene and prostate cancer aggressiveness in a Caucasian cohort. Clin Cancer Res (2010) 0.84
Inherited variations in AR, ESR1, and ESR2 genes are not associated with prostate cancer aggressiveness or with efficacy of androgen deprivation therapy. Cancer Epidemiol Biomarkers Prev (2010) 0.84
A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res (2006) 0.84
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol (2005) 0.84
Comparing dietary and other lifestyle factors among immigrant Nigerian men living in the US and indigenous men from Nigeria: potential implications for prostate cancer risk reduction. J Immigr Minor Health (2009) 0.83
Establishing the infrastructure to comprehensively address cancer disparities: a model for transdisciplinary approaches. J Health Care Poor Underserved (2013) 0.82
National Cancer Institute Prostate Cancer Genetics Workshop. Cancer Res (2011) 0.82
Genetics of prostate cancer risk. Mt Sinai J Med (2010) 0.82
The impact of common genetic variations in genes of the sex hormone metabolic pathways on steroid hormone levels and prostate cancer aggressiveness. Cancer Prev Res (Phila) (2011) 0.81
Severe hypoalbuminemia at day 90 predicts worse nonrelapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant (2010) 0.80
Prevalence and functional analysis of sequence variants in the ATR checkpoint mediator Claspin. Mol Cancer Res (2009) 0.79
Induced overexpression of phospholemman S68E mutant improves cardiac contractility and mortality after ischemia-reperfusion. Am J Physiol Heart Circ Physiol (2014) 0.79
Full-thickness grafts procured from skin overlying the sentinel lymph node basin; reconstruction of primary cutaneous malignancy excision defects. Ann Surg Oncol (2008) 0.79
Safety and chemopreventive effect of Polyphenon E in preventing early and metastatic progression of prostate cancer in TRAMP mice. Cancer Prev Res (Phila) (2014) 0.79
Clinical uncertainty of prostate cancer genetic risk panels. Sci Transl Med (2013) 0.79